Annual report pursuant to Section 13 and 15(d)

INCOME TAXES (Details)

v3.7.0.1
INCOME TAXES (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Deferred tax assets      
Net operating loss carryforwards $ 297,445 $ 276,740  
Orphan drug and research and development credits 44,348 36,387  
Deferred compensation 21,618 22,647  
Capitalized research and development expenses 1,877 1,761  
Other, net 3,069 4,966  
Total deferred tax assets 368,357 342,501  
Valuation allowance $ (368,357) $ (342,501)  
Reconciliation of the statutory federal income tax rate to the effective tax rate      
Federal statutory tax rate (as a percent) (34.00%) (34.00%) (34.00%)
Valuation allowance (as a percent) 35.00% 31.30% 32.30%
Other, net (as a percent) (1.00%) 2.70% 1.70%
Effective tax rate (as a percent) 0.00% 0.00% 0.00%